Literature DB >> 24003652

Almost everyone over 50 should be put on a statin to reduce the risk of cardiovascular disease: A protagonist view.

Pratik Sandesara1, Douglas B Bogart.   

Abstract

The burden of cardiovascular disease (CVD) in the United States (U.S.) and worldwide is immense. The total cost for CVD care in the U.S. for 2010 was over 400 billion dollars.' The levels of total cholesterol and low density lipoprotein cholesterol (LDL-C) are critical determinants for the development of CVD.2 It has been clearly established that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statin drugs), are potent LDL-C lowering agents that are the cornerstone of CVD treatment. We will review here the developing evidence to support statin therapy for primary prevention of cardiovascular disease for almost everyone over the age of 50.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24003652      PMCID: PMC6179897     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  40 in total

1.  Coronary disease among United States soldiers killed in action in Korea; preliminary report.

Authors:  W F ENOS; R H HOLMES; J BEYER
Journal:  J Am Med Assoc       Date:  1953-07-18

2.  Statins for all by the age of 50 years?

Authors:  Shah Ebrahim; Juan P Casas
Journal:  Lancet       Date:  2012-05-17       Impact factor: 79.321

3.  The relationship between statin use and open-angle glaucoma.

Authors:  Joshua D Stein; Paula Anne Newman-Casey; Nidhi Talwar; Bin Nan; Julia E Richards; David C Musch
Journal:  Ophthalmology       Date:  2012-06-21       Impact factor: 12.079

4.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

Authors:  Donald Lloyd-Jones; Robert Adams; Mercedes Carnethon; Giovanni De Simone; T Bruce Ferguson; Katherine Flegal; Earl Ford; Karen Furie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary McDermott; James Meigs; Dariush Mozaffarian; Graham Nichol; Christopher O'Donnell; Veronique Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Randall Stafford; Julia Steinberger; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan Wong; Judith Wylie-Rosett; Yuling Hong
Journal:  Circulation       Date:  2008-12-15       Impact factor: 29.690

5.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

6.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

7.  Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform?

Authors:  Kwame O Akosah; Ana Schaper; Christopher Cogbill; Paul Schoenfeld
Journal:  J Am Coll Cardiol       Date:  2003-05-07       Impact factor: 24.094

8.  Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.

Authors:  Edward J Mills; Beth Rachlis; Ping Wu; Philip J Devereaux; Paul Arora; Dan Perri
Journal:  J Am Coll Cardiol       Date:  2008-11-25       Impact factor: 24.094

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study.

Authors: 
Journal:  Lancet       Date:  2011-01-27       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.